Limited progress in hantavirus vaccine candidates continues to anchor trader consensus around a low probability of availability by the end of 2026. No candidates have advanced beyond early preclinical or Phase 1 stages in recent surveillance data, with development timelines typically spanning 10–15 years from discovery through regulatory approval due to the virus’s rodent-borne transmission and sporadic global incidence. Official monitoring by agencies such as the CDC and WHO shows no surge in dedicated funding or large-scale trials that would accelerate this process, consistent with historical patterns for low-incidence pathogens. A major outbreak or breakthrough publication could shift timelines, but current epidemiological trends and research pipelines offer little indication of such catalysts before the market resolves.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · AtualizadoHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$92,644 Vol.
$92,644 Vol.
31 dez 2026
$92,644 Vol.
$92,644 Vol.
31 dez 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Limited progress in hantavirus vaccine candidates continues to anchor trader consensus around a low probability of availability by the end of 2026. No candidates have advanced beyond early preclinical or Phase 1 stages in recent surveillance data, with development timelines typically spanning 10–15 years from discovery through regulatory approval due to the virus’s rodent-borne transmission and sporadic global incidence. Official monitoring by agencies such as the CDC and WHO shows no surge in dedicated funding or large-scale trials that would accelerate this process, consistent with historical patterns for low-incidence pathogens. A major outbreak or breakthrough publication could shift timelines, but current epidemiological trends and research pipelines offer little indication of such catalysts before the market resolves.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Mercado Aberto: May 4, 2026, 10:39 AM ET
Volume
$92,644Data de Término
31 dez 2026Mercado Aberto
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Limited progress in hantavirus vaccine candidates continues to anchor trader consensus around a low probability of availability by the end of 2026. No candidates have advanced beyond early preclinical or Phase 1 stages in recent surveillance data, with development timelines typically spanning 10–15 years from discovery through regulatory approval due to the virus’s rodent-borne transmission and sporadic global incidence. Official monitoring by agencies such as the CDC and WHO shows no surge in dedicated funding or large-scale trials that would accelerate this process, consistent with historical patterns for low-incidence pathogens. A major outbreak or breakthrough publication could shift timelines, but current epidemiological trends and research pipelines offer little indication of such catalysts before the market resolves.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$92,644Data de Término
31 dez 2026Mercado Aberto
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Limited progress in hantavirus vaccine candidates continues to anchor trader consensus around a low probability of availability by the end of 2026. No candidates have advanced beyond early preclinical or Phase 1 stages in recent surveillance data, with development timelines typically spanning 10–15 years from discovery through regulatory approval due to the virus’s rodent-borne transmission and sporadic global incidence. Official monitoring by agencies such as the CDC and WHO shows no surge in dedicated funding or large-scale trials that would accelerate this process, consistent with historical patterns for low-incidence pathogens. A major outbreak or breakthrough publication could shift timelines, but current epidemiological trends and research pipelines offer little indication of such catalysts before the market resolves.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado
Cuidado com os links externos.
Cuidado com os links externos.
Frequently Asked Questions